[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL1969004T3 - Kompozycje zawierające acylowaną insulinę i cynk oraz sposób wytwarzania tych kompozycji - Google Patents

Kompozycje zawierające acylowaną insulinę i cynk oraz sposób wytwarzania tych kompozycji

Info

Publication number
PL1969004T3
PL1969004T3 PL06841562T PL06841562T PL1969004T3 PL 1969004 T3 PL1969004 T3 PL 1969004T3 PL 06841562 T PL06841562 T PL 06841562T PL 06841562 T PL06841562 T PL 06841562T PL 1969004 T3 PL1969004 T3 PL 1969004T3
Authority
PL
Poland
Prior art keywords
compositions
insulin
zinc
making
acylated insulin
Prior art date
Application number
PL06841562T
Other languages
English (en)
Inventor
Svend Havelund
Frantisek Hubalek
Helle Birk Olsen
Ib Jonassen
Thomas Hoeg-Jensen
Anne Plum
Ulla Ribel-Madsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36888823&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1969004(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of PL1969004T3 publication Critical patent/PL1969004T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL06841562T 2005-12-28 2006-12-21 Kompozycje zawierające acylowaną insulinę i cynk oraz sposób wytwarzania tych kompozycji PL1969004T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05113021 2005-12-28
PCT/EP2006/070104 WO2007074133A2 (en) 2005-12-28 2006-12-21 Compositions comprising an acylated insulin and zinc and method of making the said compositions
EP06841562A EP1969004B1 (en) 2005-12-28 2006-12-21 Compositions comprising an acylated insulin and zinc and method of making the said compositions

Publications (1)

Publication Number Publication Date
PL1969004T3 true PL1969004T3 (pl) 2012-01-31

Family

ID=36888823

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06841562T PL1969004T3 (pl) 2005-12-28 2006-12-21 Kompozycje zawierające acylowaną insulinę i cynk oraz sposób wytwarzania tych kompozycji

Country Status (10)

Country Link
US (2) US20090074882A1 (pl)
EP (2) EP1969004B1 (pl)
JP (3) JP4808785B2 (pl)
CN (1) CN101389650B (pl)
AT (1) ATE519780T1 (pl)
DK (1) DK1969004T3 (pl)
ES (1) ES2371361T3 (pl)
PL (1) PL1969004T3 (pl)
PT (1) PT1969004E (pl)
WO (1) WO2007074133A2 (pl)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2107069T3 (pl) 2003-08-05 2013-06-28 Novo Nordisk As Nowe pochodne insuliny
ES2575984T3 (es) * 2004-11-12 2016-07-04 Novo Nordisk A/S Formulaciones estables de péptidos que contienen un análogo de GLP-1 acilado y una insulina basal
EP1846446B1 (en) 2005-02-02 2013-06-26 Novo Nordisk A/S Insulin derivatives
ES2490243T3 (es) 2005-02-02 2014-09-03 Novo Nordisk A/S Derivados de insulina
EP1969004B1 (en) 2005-12-28 2011-08-10 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
JP5202338B2 (ja) * 2006-02-27 2013-06-05 ノボ・ノルデイスク・エー／エス 新規インシュリン誘導体
US8796205B2 (en) * 2006-05-09 2014-08-05 Novo Nordisk A/S Insulin derivative
EP2386572B1 (en) * 2006-05-09 2015-07-08 Novo Nordisk A/S Insulin derivative
US9018161B2 (en) 2006-09-22 2015-04-28 Novo Nordisk A/S Protease resistant insulin analogues
US9387176B2 (en) 2007-04-30 2016-07-12 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
CN101677947B (zh) * 2007-06-13 2013-07-17 诺沃-诺迪斯克有限公司 包含胰岛素衍生物的药物制剂
JP5715418B2 (ja) * 2007-11-08 2015-05-07 ノボ・ノルデイスク・エー／エス インスリン誘導体
CN107412742B (zh) 2007-11-16 2022-03-15 诺沃—诺迪斯克有限公司 包含glp-1肽或毒蜥外泌肽-4和基础胰岛素肽的药物组合物
JP5762001B2 (ja) 2008-03-14 2015-08-12 ノボ・ノルデイスク・エー／エス プロテアーゼ安定化インスリンアナログ
BRPI0910348B1 (pt) 2008-03-18 2021-06-29 Novo Nordisk A/S Insulina estabilizada em protease acilada, composição farmacêutica compreendendo a mesma e seus usos
CN102202683A (zh) 2008-10-30 2011-09-28 诺沃-诺迪斯克有限公司 用少于每日一次的注射频率注射胰岛素来治疗糖尿病
US9180261B2 (en) 2010-01-12 2015-11-10 Dance Biopharm Inc. Preservative free insulin formulations and systems and methods for aerosolizing
US10842951B2 (en) 2010-01-12 2020-11-24 Aerami Therapeutics, Inc. Liquid insulin formulations and methods relating thereto
US20160243199A1 (en) * 2015-02-25 2016-08-25 Dance Biopharm, Inc. Liquid insulin formulations and methods relating thereto
CN102883743A (zh) 2010-05-10 2013-01-16 诺沃—诺迪斯克有限公司 用于制备胰岛素-锌复合物的方法
RS59423B1 (sr) 2010-10-27 2019-11-29 Novo Nordisk As Lečenje dijabetesa melitusa korišćenjem insulinskih injekcija davanih u različitim intervalima ubrizgavanja
JP6049625B2 (ja) 2010-10-27 2016-12-21 ノヴォ ノルディスク アー／エス 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
EP2651432A1 (en) 2010-12-14 2013-10-23 Novo Nordisk A/S Fast-acting insulin in combination with long-acting insulin
JP6110312B2 (ja) * 2011-02-01 2017-04-05 ノヴォ ノルディスク アー／エス インスリンの精製
CN102675452B (zh) 2011-03-17 2015-09-16 重庆富进生物医药有限公司 具持续降血糖和受体高结合的人胰岛素及类似物的偶联物
CN104364260B (zh) 2012-04-11 2017-02-22 诺和诺德股份有限公司 胰岛素制剂
RU2670106C2 (ru) 2012-05-01 2018-10-18 Ново Нордиск А/С Фармацевтическая композиция
EP2911655A1 (en) 2012-10-24 2015-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Tpl2 kinase inhibitors for preventing or treating diabetes and for promoting -cell survival
BR112015010799B1 (pt) 2012-11-13 2023-01-17 Adocia Composição em solução aquosa, e, formulação farmacêutica
EP2976096B1 (en) * 2013-03-20 2019-02-27 Novo Nordisk A/S Insulin dosing regimen
JP2016519127A (ja) 2013-04-30 2016-06-30 ノヴォ ノルディスク アー／エス 新規投与レジメン
AU2014333979B2 (en) 2013-10-07 2018-02-15 Novo Nordisk A/S Novel derivative of an insulin analogue
WO2015104311A1 (en) * 2014-01-09 2015-07-16 Sanofi Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
ES2630106T3 (es) 2014-10-07 2017-08-18 Cyprumed Gmbh Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
EP3273981B1 (en) 2015-03-24 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Method and pharmaceutical composition for use in the treatment of diabetes
TWI747929B (zh) * 2016-08-02 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 一種人胰島素或其類似物的醯化衍生物
DK3554534T3 (da) * 2016-12-16 2021-08-23 Novo Nordisk As Farmaceutisk sammensætning omfattende insulin
US20210040171A1 (en) * 2018-02-01 2021-02-11 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition comprising acylated derivative of human insulin analog and preparation method thereof
WO2019223752A1 (zh) 2018-05-24 2019-11-28 江苏恒瑞医药股份有限公司 一种重组人胰岛素或其类似物的前体的制备方法
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
EP3996679B1 (en) 2019-07-12 2023-09-06 Novo Nordisk A/S High concentration insulin formulation
WO2021185304A1 (zh) * 2020-03-18 2021-09-23 东莞市东阳光生物药研发有限公司 制备长脂肪链二酸衍生物的方法及其应用
WO2022111642A1 (zh) * 2020-11-27 2022-06-02 江苏恒瑞医药股份有限公司 一种制备胰岛素或其类似物的酰化衍生物的方法
EP4361174A1 (en) * 2021-06-25 2024-05-01 Gan & Lee Pharmaceuticals Co., Ltd. Acylated insulin-containing pharmaceutical composition
CN113896784B (zh) * 2021-10-18 2024-04-16 合肥天麦生物科技发展有限公司 一种胰岛素结晶的制备方法及其产品

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1212679B (de) 1957-08-03 1966-03-17 Novo Terapeutisk Labor As Verfahren zur Herstellung von Insulinloesungen
GB1042194A (en) 1962-04-30 1966-09-14 Olin Mathieson Insulin preparations
US3528960A (en) 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US3907676A (en) 1970-07-28 1975-09-23 Novo Terapeutisk Labor As Process for purifying insulin
US3868358A (en) * 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
GB1492997A (en) 1976-07-21 1977-11-23 Nat Res Dev Insulin derivatives
JPS5767548A (en) 1980-10-14 1982-04-24 Shionogi & Co Ltd Insulin analog and its preparation
US4652548A (en) 1981-08-27 1987-03-24 Eli Lilly And Company Pharmaceutical formulations comprising human insulin, human C-peptide, and human proinsulin
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
US4876322A (en) 1984-08-10 1989-10-24 Siemens Aktiengesselschaft Irradiation cross-linkable thermostable polymer system, for microelectronic applications
EP0174493B1 (de) 1984-08-17 1988-05-25 Bayer Ag Thermoplastische Formmassen mit flammwidrigen Eigenschaften
DE3433367A1 (de) 1984-09-12 1986-03-20 Robert Bosch Gmbh, 7000 Stuttgart Einrichtung zur steuerung der energiezufuhr zu einer heissen stelle
US5008241A (en) 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
DK113585D0 (da) 1985-03-12 1985-03-12 Novo Industri As Nye peptider
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
JPS61226115A (ja) 1985-03-30 1986-10-08 Mitsubishi Metal Corp 線条体押し出し機
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US4764592A (en) 1987-04-23 1988-08-16 Eli Lilly And Company Crystalline human proinsulin and process for its production
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
JPH01254699A (ja) 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
DE3827533A1 (de) * 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
AU641631B2 (en) 1988-12-23 1993-09-30 Novo Nordisk A/S Human insulin analogues
NZ232375A (en) 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
AU641721B2 (en) * 1989-12-21 1993-09-30 Novo Nordisk A/S Insulin preparations containing nicotinic acid or nicotinamide
DK45590D0 (pl) 1990-02-21 1990-02-21 Novo Nordisk As
DK175491D0 (da) 1991-10-18 1991-10-18 Novo Nordisk As Apparat
KR100266502B1 (ko) 1991-12-20 2000-09-15 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 성장호르몬과히스티딘으로이루어지는안정화된약학제제
US5672581A (en) 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
US6869930B1 (en) * 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
KR100310122B1 (ko) 1993-09-17 2002-04-24 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 아실화된인슐린
US6011007A (en) * 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US5652216A (en) 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
AU3562195A (en) 1994-10-04 1996-04-26 Novo Nordisk A/S Preparations containing aspb28 human insulin and nicotinamide
US5646242A (en) 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US5830999A (en) * 1995-01-26 1998-11-03 Regents Of The University Of California Stabilization of insulin through ligand binding interations
CN1196061A (zh) 1995-03-17 1998-10-14 诺沃挪第克公司 胰岛素衍生物
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
CN1151842C (zh) 1995-07-27 2004-06-02 基因技术股份有限公司 稳定等渗的冻干蛋白制剂
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
US5866538A (en) * 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
ES2230607T3 (es) 1996-07-11 2005-05-01 Novo Nordisk A/S Metodo selectivo de acilacion.
US5905140A (en) * 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
EP0821006B1 (de) 1996-07-26 2004-04-21 Aventis Pharma Deutschland GmbH Insulinderivate mit erhöhter Zinkbindung
IL119029A0 (en) 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
DE69806582T2 (de) * 1997-03-20 2003-02-13 Novo Nordisk A/S, Bagsvaerd Verfahren zur herstellung eines therapeutischen puders durch copräzipitation von insulin und einem absorptionsverstärker
EP0971729B1 (en) 1997-03-20 2002-07-03 Novo Nordisk A/S Therapeutic powder formulation for pulmonary administration, containing crystalline insulin
US7097845B2 (en) 1997-04-23 2006-08-29 Jacob Sten Petersen Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
DK1283051T3 (da) 1997-06-13 2006-10-16 Lilly Co Eli Stabile insulinformuleringer
CO4750643A1 (es) 1997-06-13 1999-03-31 Lilly Co Eli Formulacion estable de la insulina que contiene l-arginina y protamina
EA200000453A1 (ru) 1997-10-24 2000-10-30 Эли Лилли Энд Компани Композиции нерастворимого инсулина
US20020155994A1 (en) * 1997-10-24 2002-10-24 Svend Havelund Aggregates of human insulin derivatives
US6451762B1 (en) * 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
BR9813128A (pt) 1997-10-24 2000-08-15 Novo Nordisk As Agregado solúvel em água de derivados de insulina, derivado de insulina, preparação farmacêutica, e, processo para tratamento de diabetes mellitus
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
CA2309955A1 (en) 1997-11-12 1999-05-20 Alza Corporation Method for decreasing self-association of polypeptides
CO4970787A1 (es) * 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
AU1870099A (en) * 1998-01-09 1999-07-26 Novo Nordisk A/S Stabilised insulin compositions
US6211144B1 (en) * 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
ES2177323T3 (es) * 1998-10-16 2002-12-01 Novo Nordisk As Preparaciones de insulina concentradas estables para la administracionpor via pulmonar.
ES2180511T3 (es) * 1999-01-26 2003-02-16 Lilly Co Eli Formulaciones monodispersas de analogos de insulina acilados hexamericos.
CN101683522B (zh) 1999-02-22 2013-05-01 巴克斯特国际有限公司 新的无白蛋白的因子ⅷ制剂
EP1173482A1 (en) 1999-04-27 2002-01-23 Eli Lilly And Company Insulin crystals for pulmonary administration
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US6652886B2 (en) * 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
JP4624600B2 (ja) * 2001-06-08 2011-02-02 トヨタ自動車株式会社 焼結合金、その製造方法およびバルブシート
US20030119734A1 (en) 2001-06-28 2003-06-26 Flink James M. Stable formulation of modified GLP-1
JP2004537580A (ja) 2001-08-10 2004-12-16 エピックス メディカル， インコーポレイテッド 延長された循環半減期を有するポリペプチド結合体
US20030068361A1 (en) 2001-10-09 2003-04-10 Rimona Margalit Liposome-encapsulated insulin formulations
HUP0700126A2 (en) 2001-12-20 2007-06-28 Lilly Co Eli Insulin molecule having protracted time action
WO2003075950A1 (en) * 2002-03-13 2003-09-18 Novo Nordisk A/S Minimising body weight gain in insulin treatment
WO2003094951A1 (en) 2002-05-07 2003-11-20 Novo Nordisk A/S Soluble formulations comprising insulin aspart and insulin detemir
WO2003094956A1 (en) * 2002-05-07 2003-11-20 Novo Nordisk A/S Soluble formulations comprising monomeric insulin and acylated insulin
US20050232899A1 (en) 2002-05-31 2005-10-20 Aradigm Corporation Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US20040002451A1 (en) 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
KR100615389B1 (ko) 2002-08-23 2006-08-25 (주)헬릭서 다래 추출물을 함유하는 알러지성 질환 및 비알러지성염증 질환의 예방 및 개선용 건강 기능 식품
WO2004039392A2 (en) 2002-10-29 2004-05-13 Alza Corporation Stabilized, solid-state polypeptide particles
US20040138099A1 (en) * 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
RU2358738C2 (ru) 2003-02-07 2009-06-20 Адзиномото Ко., Инк. Лекарственные средства для лечения сахарного диабета
EP1597367B1 (en) 2003-02-19 2010-07-07 Novartis AG Glycoprotein antigen sima135 expressed in metastatic human tumor cells
AR046485A1 (es) * 2003-03-04 2005-12-14 Technology Dev Company Ltd Sistema de administracion para drogas y terapia celular
ATE547114T1 (de) 2003-06-25 2012-03-15 Novo Nordisk Healthcare Ag Flüssige zusammensetzungen von factor vii polypeptiden
US20050054818A1 (en) 2003-07-02 2005-03-10 Brader Mark Laurence Crystalline compositions for controlling blood glucose
WO2005005477A2 (en) 2003-07-11 2005-01-20 Novo Nordisk A/S Stabilised insulin compositions
PL2107069T3 (pl) 2003-08-05 2013-06-28 Novo Nordisk As Nowe pochodne insuliny
PT2107069E (pt) 2003-08-05 2013-04-23 Novo Nordisk As Novos derivados de insulina
KR20120104619A (ko) 2003-08-14 2012-09-21 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 액상 수성 약학적 조성물
JP5518282B2 (ja) 2003-09-01 2014-06-11 ノヴォ ノルディスク アー／エス 安定なペプチドの製剤
ES2229931B1 (es) 2003-10-03 2006-01-16 Grifols, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
WO2005047508A1 (en) 2003-11-14 2005-05-26 Novo Nordisk A/S Processes for making acylated insulin
CA2551510C (en) 2003-12-23 2013-07-30 Pharmacia Corporation Stable growth hormone liquid formulation
EP1740154B1 (en) 2004-03-12 2009-06-17 Biodel, Inc. Insulin compositions with improved absorption
BRPI0510527A (pt) 2004-06-01 2007-10-30 Ares Trading Sa método de estabilização de proteìnas
WO2006008238A1 (en) 2004-07-16 2006-01-26 Novo Nordisk A/S Method for selective acylation
ATE476967T1 (de) 2004-08-12 2010-08-15 Schering Corp Stabile pegylierte interferon-formulierung
PT1778723E (pt) 2004-08-17 2013-01-25 Regeneron Pharma Formulações de antagonista de il-1
ES2575984T3 (es) 2004-11-12 2016-07-04 Novo Nordisk A/S Formulaciones estables de péptidos que contienen un análogo de GLP-1 acilado y una insulina basal
ES2391776T3 (es) 2004-11-22 2012-11-29 Novo Nordisk A/S Formulaciones solubles, estables conteniendo insulina con una sal de protamina
JP2008528509A (ja) 2005-01-21 2008-07-31 アルザ コーポレイション 少なくとも１つの対イオンを含む、向上した安定性でマイクロニードルをコーティングするための治療用ペプチド製剤
EP1846446B1 (en) * 2005-02-02 2013-06-26 Novo Nordisk A/S Insulin derivatives
ES2490243T3 (es) 2005-02-02 2014-09-03 Novo Nordisk A/S Derivados de insulina
WO2007041481A1 (en) 2005-09-29 2007-04-12 Biodel, Inc. Rapid acting and prolonged acting insulin preparations
KR20080064171A (ko) 2005-10-20 2008-07-08 나스텍 파마수티컬 컴퍼니 인코포레이티드 속효성 인슐린의 비강내 투여
EP1969004B1 (en) 2005-12-28 2011-08-10 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
JP5202338B2 (ja) 2006-02-27 2013-06-05 ノボ・ノルデイスク・エー／エス 新規インシュリン誘導体
CA2649109A1 (en) 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations
CN101454019A (zh) 2006-04-12 2009-06-10 百达尔公司 速效和长效胰岛素联合制剂
EP2386572B1 (en) 2006-05-09 2015-07-08 Novo Nordisk A/S Insulin derivative
US8796205B2 (en) 2006-05-09 2014-08-05 Novo Nordisk A/S Insulin derivative
WO2007135117A2 (en) 2006-05-24 2007-11-29 Novo Nordisk A/S Soluble, stable insulin-containing formulations
US9018161B2 (en) 2006-09-22 2015-04-28 Novo Nordisk A/S Protease resistant insulin analogues
CN101677947B (zh) * 2007-06-13 2013-07-17 诺沃-诺迪斯克有限公司 包含胰岛素衍生物的药物制剂
CN101784563B (zh) 2007-08-15 2015-02-04 诺沃-诺迪斯克有限公司 具有包括含亚烷基二醇的氨基酸的重复单位的酰基部分的胰岛素
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
JP5715418B2 (ja) 2007-11-08 2015-05-07 ノボ・ノルデイスク・エー／エス インスリン誘導体
CN107412742B (zh) * 2007-11-16 2022-03-15 诺沃—诺迪斯克有限公司 包含glp-1肽或毒蜥外泌肽-4和基础胰岛素肽的药物组合物
BRPI0910348B1 (pt) 2008-03-18 2021-06-29 Novo Nordisk A/S Insulina estabilizada em protease acilada, composição farmacêutica compreendendo a mesma e seus usos
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
CN102202683A (zh) 2008-10-30 2011-09-28 诺沃-诺迪斯克有限公司 用少于每日一次的注射频率注射胰岛素来治疗糖尿病
CN102883743A (zh) 2010-05-10 2013-01-16 诺沃—诺迪斯克有限公司 用于制备胰岛素-锌复合物的方法
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
EP2389945A1 (en) 2010-05-28 2011-11-30 Sanofi-Aventis Deutschland GmbH Pharmaceutical composition comprising AVE0010 and insulin glargine
JP6049625B2 (ja) 2010-10-27 2016-12-21 ノヴォ ノルディスク アー／エス 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
RS59423B1 (sr) 2010-10-27 2019-11-29 Novo Nordisk As Lečenje dijabetesa melitusa korišćenjem insulinskih injekcija davanih u različitim intervalima ubrizgavanja
JP6110312B2 (ja) 2011-02-01 2017-04-05 ノヴォ ノルディスク アー／エス インスリンの精製
KR101836957B1 (ko) 2011-03-01 2018-03-09 제이디에스 테라퓨틱스, 엘엘씨 당뇨병, 저혈당 및 관련 장애를 치료 및 예방하기 위한 인슐린과 크롬을 포함하는 조성물
WO2013037754A2 (en) 2011-09-13 2013-03-21 Novo Nordisk A/S Adaptive system for optimizing a drug dosage regimen over time
CN104364260B (zh) 2012-04-11 2017-02-22 诺和诺德股份有限公司 胰岛素制剂
RU2670106C2 (ru) 2012-05-01 2018-10-18 Ново Нордиск А/С Фармацевтическая композиция
EP2976096B1 (en) 2013-03-20 2019-02-27 Novo Nordisk A/S Insulin dosing regimen
US9839579B2 (en) 2013-04-24 2017-12-12 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
JP2016519127A (ja) 2013-04-30 2016-06-30 ノヴォ ノルディスク アー／エス 新規投与レジメン
PE20211264A1 (es) 2017-08-17 2021-07-15 Novo Nordisk As Analogos de insulina acilados novedosos y usos de estos

Also Published As

Publication number Publication date
DK1969004T3 (da) 2011-11-28
EP1969004A2 (en) 2008-09-17
JP4808785B2 (ja) 2011-11-02
WO2007074133A2 (en) 2007-07-05
US20140328943A1 (en) 2014-11-06
CN101389650B (zh) 2012-10-10
JP5026567B2 (ja) 2012-09-12
EP1969004B1 (en) 2011-08-10
PT1969004E (pt) 2011-11-25
JP2011121963A (ja) 2011-06-23
JP2011006428A (ja) 2011-01-13
JP2009522231A (ja) 2009-06-11
CN101389650A (zh) 2009-03-18
US20090074882A1 (en) 2009-03-19
ATE519780T1 (de) 2011-08-15
ES2371361T3 (es) 2011-12-30
US11167035B2 (en) 2021-11-09
EP2505593A1 (en) 2012-10-03
WO2007074133A3 (en) 2007-10-11

Similar Documents

Publication Publication Date Title
PL1969004T3 (pl) Kompozycje zawierające acylowaną insulinę i cynk oraz sposób wytwarzania tych kompozycji
TW200637490A (en) Fertilizer-compatible composition
HK1126235A1 (en) Two-part curable composition and polyurethane-polysiloxane resin mixture obtained therefrom
IL241654B (en) Compositions comprising recombinant arylsulfatase and uses thereof for the treatment of metachromatic leukodystrophy
PL3398606T3 (pl) Kompozycje otrzymane z mikroalg poprawiające zdrowie i wygląd skóry
WO2010069496A8 (de) Knochenschraube
WO2007081978A3 (en) Modulators of hepatocyte growth factor / c-met activity
IL189972A0 (en) Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
HK1110508A1 (en) Compositions and methods of their use for improving the condition and appearance of skin
IL211336A0 (en) Oxygen scavenger for low moisture environment and methods of using the same
WO2007038627A3 (en) Stabilized antimicrobial compositions and related methods of preparation
ZA200705954B (en) Processing of tobacco with high content of tobacco flake cuts
IL187405A0 (en) Methods and compositions for the treatment of pain
EP1909809A4 (en) METHOD AND COMPOSITION FOR TREATING DIABETES AND ITS COMPLICATIONS
EP2010164A4 (en) COMPOSITIONS COMPRISING S-NITROSOTHIOLS FOR TREATING HEPATIC STEATOSES, OBESITY AND OTHER MATABOLIC SYNCHROME-RELATED DISEASES AND USE THEREOF
EP1786265A4 (en) NEW COMPOSITIONS AND PROCESSING METHODS
GB0601950D0 (en) Compositions and methods of treating diabetes
EP2096927A4 (en) THERAPEUTIC COMPOSITIONS AND METHODS OF TREATING WITH CAPSIANOSIDE COMPOUNDS
EP1633557A4 (en) COMPOSITIONS AND METHODS FOR BLINKING AND ASSIGNING ANTI-CORROSION PROPERTIES TO ZINC OR OTHER ACTIVE METALS
HU0105261D0 (en) Natural based composition with organic bounds containing iodine for introducing iodine into living organs and processes for their production
EP2092838A4 (en) TOBACCO CATALYST MIXTURES FOR REDUCING THE CONTENT OF TOXIC COMPOUNDS IN TOBACCO
EP1962882A4 (en) COMPOSITIONS AND METHOD FOR TREATING DIABETES
WO2006092650A3 (en) A composition for creating an artificial bone -marrow like environment and use thereof
EP1623222A4 (en) RANBP2 COMPRISING A MODIFIER OF THE PTEN / IGF PATHWAY AND METHODS OF USE
GB0504657D0 (en) Compositions and methods of treatment